Influence of a muramyl dipeptide on human blood leukocyte functions and their membrane antigens.
Murabutide, which belongs to the immunomodulator family of muramyl peptides, was applied directly to fresh human blood to evaluate changes in leukocyte properties. After blood incubation with murabutide, lymphocytes presented a higher responsiveness to T-mitogens, and monocytes and polymorphonuclear cells exhibited an increase in their capacity to produce hydrogen peroxide. In addition, murabutide treatment enhanced phagocytic activity of neutrophils, whereas monocytes presented a decrease in this activity. Some surface markers were also investigated in the distinct leukocyte populations. After incubation with murabutide, a larger number of lymphocytes expressed Ta1 antigen (CD W26) and transferrin receptor (CD 71). In contrast, expression of interleukin-2 receptor (CD 25) was slightly decreased. Monocytes from treated blood displayed a larger number of receptors for C3bi (CD 11b), whereas the surface marker CD 14 and the class I receptor for the Fc portion of IgG were down-regulated. Activation of polymorphonuclear cells by murabutide was confirmed by the up-regulation of the C3bi receptor, Fc receptor, and CD 14 surface antigen. The effects of murabutide on leukocytes described in this paper may contribute to understanding mechanisms of the modulating activity of muramyl peptides on specific and nonspecific immunity.
Riveau
G J
GJ
Laboratoire d'Immunopharmacologie Expérimentale, CNRS UPR 405, Institut Biomédical des Cordeliers, Paris, France.
Brunel-Riveau
B G
BG
Audibert
F M
FM
Chedid
L A
LA
D000119:Acetylmuramyl-Alanyl-Isoglutamine / Q000031:analogs & derivatives* / Q000494:pharmacology; D000911:Antibodies, Monoclonal; D015703:Antigens, CD / Q000378:metabolism*; D000943:Antigens, Differentiation / Q000276:immunology; D000944:Antigens, Differentiation, B-Lymphocyte / Q000378:metabolism; D015214:Antigens, Differentiation, Myelomonocytic / Q000378:metabolism; D000945:Antigens, Differentiation, T-Lymphocyte / Q000378:metabolism; D018819:Dipeptidyl Peptidase 4; D005434:Flow Cytometry; D006801:Humans; D006861:Hydrogen Peroxide / Q000378:metabolism; D066298:In Vitro Techniques; D018950:Lipopolysaccharide Receptors; D008213:Lymphocyte Activation; D008214:Lymphocytes / Q000276:immunology*; D016177:Macrophage-1 Antigen / Q000378:metabolism; D009000:Monocytes / Q000276:immunology*; D009504:Neutrophils / Q000276:immunology*; D010587:Phagocytosis; D011961:Receptors, Fc / Q000276:immunology; D017452:Receptors, IgG; D015375:Receptors, Interleukin-2 / Q000378:metabolism; D011990:Receptors, Transferrin / Q000378:metabolism
D000911:Antibodies, Monoclonal; D015703:Antigens, CD; D000943:Antigens, Differentiation; D000944:Antigens, Differentiation, B-Lymphocyte; D015214:Antigens, Differentiation, Myelomonocytic; D000945:Antigens, Differentiation, T-Lymphocyte; C068126:CD71 antigen; D018950:Lipopolysaccharide Receptors; D016177:Macrophage-1 Antigen; D011961:Receptors, Fc; D017452:Receptors, IgG; D015375:Receptors, Interleukin-2; D011990:Receptors, Transferrin; D000119:Acetylmuramyl-Alanyl-Isoglutamine; C033575:murabutide; D006861:Hydrogen Peroxide; D018819:Dipeptidyl Peptidase 4